Important Notice to Regeneron Pharmaceuticals, Inc. Shareholders
NEW YORK, Feb. 20, 2025 – The Gross Law Firm, a leading securities fraud law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (REGN) in the United States District Court for the Southern District of New York. This lawsuit alleges that Regeneron Pharmaceuticals, Inc. and certain of its top executives violated the Securities Exchange Act of 1934.
Details of the Lawsuit
The complaint alleges that defendants made false and misleading statements and failed to disclose material information regarding Regeneron’s Eylea drug. Specifically, the complaint alleges that Regeneron and its executives knew, or should have known, that Eylea was experiencing decreased sales due to increased competition, but failed to disclose this information to investors. Instead, they issued positive statements about the drug’s sales and revenue growth.
Impact on Regeneron Shareholders
As a result of this alleged securities fraud, Regeneron shareholders who purchased or otherwise acquired the Company’s securities between January 1, 2023, and December 31, 2024, inclusive (the “Class Period”), may be entitled to recover damages and other remedies. The complaint seeks to recover damages on behalf of all Regeneron shareholders who purchased or otherwise acquired Regeneron securities during the Class Period.
Global Implications
This lawsuit has significant implications not just for Regeneron shareholders, but for the broader investment community as well. It underscores the importance of transparency and honesty in corporate communications, particularly in the pharmaceutical industry. As investors increasingly rely on company disclosures to make informed decisions, it is crucial that these disclosures are accurate and timely.
Additional Information
If you wish to review a copy of the Complaint, please contact The Gross Law Firm at 888-297-1030 or [email protected]. If you have inquires or would like to learn more about this notice or your rights as a Regeneron shareholder, please visit our website at www.grosslawfirm.com. You may also contact The Gross Law Firm by email at [email protected].
Conclusion
The Gross Law Firm is committed to fighting for the rights of shareholders, and we will continue to closely monitor the Regeneron Pharmaceuticals, Inc. case as it develops. We encourage all Regeneron shareholders to stay informed and to contact us with any questions or concerns they may have.
- Regeneron Pharmaceuticals, Inc. is the subject of a class action lawsuit alleging securities fraud.
- The lawsuit alleges that Regeneron and certain executives made false and misleading statements regarding the company’s Eylea drug.
- Regeneron shareholders who purchased or otherwise acquired the company’s securities between January 1, 2023, and December 31, 2024, may be entitled to recover damages and other remedies.
- The lawsuit highlights the importance of transparency and honesty in corporate communications, particularly in the pharmaceutical industry.
- The Gross Law Firm is committed to fighting for the rights of shareholders and encourages all Regeneron shareholders to stay informed.
